CJC-1295 Without DAC Muscle Growth Peptide MOD GRF 1-29 CJC-1295 CJC 1295 CJC1295 2mg

CJC-1295 Without DAC

Description:
CJC-1295 DAC is a long acting Hormone Releasing Hormone, which causes the anterior pituitary to release more hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

Usage:

CJC1295 DAC has shown some amazing results as a hormone releasing hormone ;GHRH; analog; Not onlyhas CJC1295 shown the ability to increase hormone and secretion and its benefits; but it has been able to do so in very large amounts; Recent research studies have shown that CJC - 1295 stimulates GH and Secretion; and will keep a steady increase with no increase in prolactin; leading to intense fat loss; and increases protein synthesis; CJC-1295 DAC is a long acting Hormone Releasing Hormone; which causes the anterior pituitary to release more hormone; The objective of the peptide was to treat visceral fat deposits in obese AIDS patients; as increased levels of exogenous are presumed to increase lipolysis ;fat loss; The clinical research was ultimately successful for most research subjects; Ghrelin; released from the gut; which circulates and acts as a hunger hormone; has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse; An example of a GHRP ;GH Releasing Peptide; is Hexarelin or GHRP2; CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the secretogues.

Two types of CJC 1295 :
GHRH (growth hormone releasing hormone) is produced in the hypothalamus. Its pulsatile release from the hypothalamus triggers pulsatile release of GH in the pituitary gland. GHRH has a very short half-life of a few minutes (half-life = the time it takes to remove half of a substance from the blood. The shorter the half-life, the faster the substance is eliminated from the body and the less it affects the body).

Although with MOD GRF 1-29, whose modification has resulted in larger peptide bonds, users still need to inject GHRP two to three times a day for maximum effect, when drug affinity complex (DAC) is added to CJC 1295, Extending its half-life to 8 days while providing smaller GH pulses.

The first 29 amino acids of GHRH are the active segment. They are available in the form of the artificial peptide Sermorelin. Sermorelin was further modified to extend its half-life to 30 minutes. This is called CJC 1295. CJC-1295 is further modified by adding DAC (Drug Affinity Complex) to it. DAC binds to a blood protein called albumin, extending its half-life to 8 days. It's called the CJC 1295 + DAC. CJC 1295 can also be compounded in a non-DAC form to simulate a more normal physiological GH peak every night. The longer albumin-binding half-life of DAC means that injections only need to be given once or twice a week. However, the long half-life and relatively constant blood levels provide a constant stimulus for the release of GH from the pituitary via the GHRH receptors, which are not physiological. This reduces the GH pulse amplitude, which will result in less GH tissue stimulation. When a person sees the words CJC 1295 without DAC, it actually means they are looking at the MOD GRF 1-29. This tetra-substituted peptide is a modified form of the original GRF 1-29 peptide, commonly known as: Semorelin. Due to the extremely short half-life of the original GRF 1-29, chemists modified the peptide to provide longer bioactivity, thereby reducing metabolic clearance.